Clinical Trials

2 trials
RecentStart dateEnrollment
Antibodies × Breast × Clear all
NCT06451497 2026-04-02

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Zumutor Biologics Inc.

Phase 1 Recruiting
100 enrolled
BreastGastrointestinalGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms